Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas

References

• Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO Classification of Tumour of the Central Nervous System. Acta Neuropathol.114(2), 97–109 (2007). Erratum in: Acta Neuropathol.114(5), 547 (2007).
   PubMed Web of Science ®Google Scholar
• Walker MD, Alexander E Jr, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J. Neurosurgery49(3), 333–343 (1978).
   PubMed Web of Science ®Google Scholar
• Fine HA, Dean KB, Loeffler JS et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer72(11), 3367 (1993).
   PubMedGoogle Scholar
• Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet359(9311), 1011–1018 (2002).
   PubMed Web of Science ®Google Scholar
• Spiegel BM, Esrailian E, Laine L Chamberlain MC. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs21(9), 775–787 (2007).
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol.17(8), 2572–2578 (1999).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Yung WK, Albright RE, Olson J et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer83(5), 588–593 (2000).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Yung WK, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J. Clin. Oncol.17(9), 2762–2771 (1999).
   PubMed Web of Science ®Google Scholar
• Wick WW, Weller M; Neuro-oncology Working Group of the German Cancer Society et al. NOA-04 randomized Phase III study of sequential radiochemotherapy of oligoastrocytic tumors of WHO-grade III with PCV or temozolomide. J. Clin. Oncol.28(15S), LBA2001 (2010).
   Web of Science ®Google Scholar
• Cairncross G, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Oncology Group trial 9402. J. Clin. Oncol.24(18), 2707–2714 (2006).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine and vincristine improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer Phase III trial. J. Clin. Oncol.24(18), 2715–2722 (2006).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Chinot O, Boogerd W. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group Phase II Study 26972. Ann. Oncol.14(4), 599–602 (2003).
   PubMed Web of Science ®Google Scholar
• Triebels VHJM, Taphoorn MJ, Brandes AA. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology63(5), 904–906 (2004).
   PubMed Web of Science ®Google Scholar
• Mirimanoff R-O, Gorlia T, Mason W et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 Phase III randomized trial. J. Clin. Oncol.24(16), 2563–2569 (2006).
   PubMed Web of Science ®Google Scholar
• Perry JR, Mason WP, Belanger K et al. The temozolomide RESCUE study: a Phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma. J. Clin. Oncol.26(Suppl.), 2010 (2008).
   Google Scholar
• Brem SS, Bierman PJ, Black P et al. Central nervous system cancers: clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw.3, 644–690 (2005).
   PubMedGoogle Scholar
• Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med.343(19), 1350–1354 (2000).
   PubMed Web of Science ®Google Scholar
• Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol.20(9), 2388–2399 (2002).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature455(7216), 1061–1068 (2008).
   PubMed Web of Science ®Google Scholar
• Silber JR, Blank A, Bobola MS, Ghatan S, Kolstoe DD, Berger MS. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin. Cancer Res.5(4), 807–814 (1999).
   PubMed Web of Science ®Google Scholar
• Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin. Cancer Res.12(2), 328–331 (2006).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Liu L, Herman JG. Correlation of O6-methylguinine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol.26(25), 4189–4199 (2008).
   PubMed Web of Science ®Google Scholar
• Gerber DE, Grossman SA, Zeltzman M Parisi MA, Kleinberg L. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neurooncology9(1), 47–52 (2007).
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Lesser G et al. Iatrogenic immunosuppression in patients with newly diagnosed high-grade gliomas. J. Clin. Oncol.25(18 Suppl.), 2012 (2007).
   PubMedGoogle Scholar
• Chamberlain MC, Raizer J. Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. J. Neuro. Oncol.93(2), 229–232 (2008).
   PubMedGoogle Scholar
• Armstrong TS, Cao Y, Vera E et al. Pharmacoepidemiology of myelotoxicity (TOX) with temozolomide (TMX) in malignant glioma patients. J. Clin. Oncol.26(15S), S513 (2008).
   Google Scholar
• Su YW, Chang MC, Chiang MF, Hsieh RK. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J. Neurooncol.71(3), 315–318 (2005).
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardin SA, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25(30), 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology70(10), 779–787 (2008).
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol.27, 740–745 (2009).
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol.27, 4753–4740 (2009).
   Google Scholar
• Lamborn KR, Yung WK, Chang SM et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol.10(2), 162–170 (2008).
   PubMed Web of Science ®Google Scholar
• Nabors LB, Mikkelsen T, Rosenfeld SS et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol.25(13), 1651–1657 (2007).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine–glycine–aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol.26(34), 5610–5617 (2008).
   PubMed Web of Science ®Google Scholar
• Mrugala M, Chamberlain MC. Mechanism of disease: temozolomide and glioblastoma – a look to the future. Nat. Clin. Pract. Oncol.5(8), 476–486 (2008).
   PubMedGoogle Scholar